Gonadal Dysgenesis is any of a multitude of conditions that can cause impaired development of the gonads: the testes or ovaries. The most notable of these conditions is Turner syndrome a quite common disorder affecting 1 in every 2500 live female births and possess a vast array of associated symptoms and complications. Although there are a large number of syndromes that have gonadal dysgenesis as a component this article will focus on Turner syndrome as well as 46, XX, 46, XY, and mosaic forms of gonadal dysgenesis. Understanding the genetics behind gonadal dysgenesis will allow clinicians to better predict the disorder’s phenotypic presentation; in turn, improving both screening methods for associated medical problems and the ongoing care of those medical problems. This article will explore the cellular, biochemical, and molecular basis behind the genetic processes that cause gonadal dysgenesis and go on to study the clinical implications of this subset of disorders and the genetics behind this chromosomal condition.
Gonadal dysgenesis is a genetic condition due to errors in cell division and or alterations in genetic material leading to complete or partial loss of gonadal development. The development of gonadal dysgenesis begins early on either at fertilization or shortly after in early stages of the embryo and fetus. Complete gonadal dysgenesis genotypes are known as either 46, XX or 46, XY. These patients with full gonadal dysgenesis exhibit streak gonads, female external genitalia and hypogonadotropic hypogonadism with associated amenorrhea and lack of secondary sexual characteristics but none of the other features of Turner syndrome described below. The 46, XX type may develop due to genetic mutations or environmental factors affecting ovarian development leading to ineffective ovaries. 46, XX type gonadal dysgenesis is on the spectrum of conditions that cause premature ovarian failure. The XY type of complete gonadal dysgenesis also called Swyer syndrome, typically develops due to mutations of genes in the SRY sex determining region of the Y chromosome; multiple possible genes have been implicated here, but in many of the individual cases an exact cause is unknown. Multiple genotypes have been discovered among Turner syndrome patients; the typical 45X type, as well as mosaic types such as 45X/46XX, 45X/46XX/47XXX, 45X/46XY considered partial gonadal dysgenesis. Additionally, some mosaics contain isochromosomes, ring chromosomes, and Xq deletions. Studies have found that as suspected mosaic forms of the disease tend to have decreased symptoms and phenotypic presentation due to some cell lines having normal genetic information.
The development of Turner syndrome stems from meiotic and mitotic errors that lead to a lack of a second X chromosome. Turner syndrome is known for a collection of symptoms including short stature, webbed neck, widely spaced nipples, amenorrhea and infertility, fetal hydrops, and cardiac problems such as a bicuspid aortic valve or coarctation of the aorta. Turner syndrome can cause a multitude of other conditions as well such as horseshoe kidney and sensorineural hearing loss. Most girls with Turner syndrome tend to have a normal intelligence level but may have issues with verbal and social skills. The specific phenotypic presentations and manifestations of the different types of gonadal dysgenesis, as well as the mechanisms leading to each type, will be discussed below.
Two of the cellular processes involved in the development of gonadal dysgenesis include meiosis and mitosis. Mitosis is the process of cellular division in which DNA replication completes, and sister chromatids are separated to produce two identical cells. Meiosis, on the other hand, is a cellular division with two separate divisions. The first step of meiosis (meiosis I) after DNA replication homologous chromosomes are paired and may undergo crossover recombination with the exchange of DNA strands between the chromosomes. At the end of meiosis I homologous chromosomes separate and produce two new cells. Meiosis II results in these two cells completing another division in which sister chromatids separate producing four cells. These cells produced by meiosis contain half the genetic material of the parent cell that started the process. The Turner syndrome type of gonadal dysgenesis can be the result of nondisjunction of sex chromosomes during either mitosis or meiosis. Nondisjunction results in unequal amounts of genetic material in the daughter cells produced. Non-disjunction typically occurs during meiosis I resulting in homologous chromosomes fail to separate. The effect of meiotic non-disjunction is gametes: ova or sperm that contain only 22 chromosomes instead of 23. Turner syndrome can be the result of an ovum lacking an X chromosome fertilized by a 23 X spermatozoon, or can be the result of a spermatozoon lacking an X or Y chromosome fertilizing a normal ovum resulting in the typical 45, X. Recent studies have found that 70 to 80% of Turner syndrome cases are the result of the loss of the paternal sex chromosome. FISH studies have found increased amounts of X and Y chromosomes in ejaculated sperm indicating non-disjunction. However, Turner syndrome is relatively common, and if meiotic non-disjunction were the only cause we would expect to see the similar incidence of other disorders such as 47, XXY, 47, XYY, and 47, XXX, but we do not.
The exact mechanisms that make Turner syndrome so much more common than these other chromosomal disorders are unclear, but the belief is that non-disjunction and chromosomal loss during the first few rounds of mitosis in the embryo is the cause. Non-disjunction during mitosis in the early stages of the fetus can also result in the formation of two separate lines of somatic cells 45X/46XX or 45X/46XY. The development of two cell lines of differing genetic makeup is called mosaicism and results in cells across the body having different genetic material which can also result in different phenotypic presentations in different parts of the body. Pure 46, XX gonadal dysgenesis is typically caused by alterations to genetic information needed for ovarian development which is present at the proximal Xp and distal Xq regions of the X chromosome. These alterations include gene translocations, deletions, and mutations. As discussed above during meiosis I homologous chromosomes can undergo crossing over and during this period translocations, and deletions can occur. The mutations causing 46, XX gonadal dysgenesis, can be sporadic or familial. Mutations in genes coding for the FSH receptor of the ovaries have implications in familial and sporadic cases. Analysis of pedigrees of families with girls with 46, XX gonadal dysgenesis have found an autosomal recessive pattern although all the possible genes and mutations involved remain undiscovered. A large number of 46, XX gonadal dysgenesis cases have links with the autosomal recessive condition congenital adrenal hyperplasia. Congenital adrenal hyperplasia is most often caused by a 21-hydroxylase enzyme deficiency, which leads to a buildup of the precursor for the enzyme 17-hydroxyprogesterone which is converted to testosterone causing virilization. In addition to the genetic causes of 46 XX gonadal dysgenesis, the disorder can also stem from autoimmune disease, infection, and infarct. Complete 46, XY gonadal dysgenesis is due to deletion of the SRY gene in 10-15% of cases and due to a mutation in SRY or DDH genes in another 10-15% of cases. True agonadism or a complete lack of gonads is yet another type of gonadal dysgenesis; however the exact mechanisms involved are unclear, but mutations in the WT1 gene have been seen in some cases.
46, XX Pure Gonadal Dysgenesis
46, XY Pure Gonadal Dysgenesis
46, XX Pure Gonadal Dysgenesis
46, XY Pure Gonadal Dysgenesis
The mechanisms of gonadal dysgenesis and specifically turner syndrome, 46 XX, 46 XY and mosaic forms of gonadal dysgenesis have been discussed in detail above. Although many genes have links with gonadal development and sexual differentiation, as well as a multitude of possible mutations, deletions, polymorphisms, and translocations associated with Turner syndrome, 46 XX, 46 XY and mosaic forms the exact mechanisms and genetic causes behind these disorders evades complete elucidation. DNA sequencing technologies have allowed investigations into specific genetic causes of these disorders. However, the particular pathway the genetic alterations go down to cause the phenotype we see are often unclear. The advancement of functional assays including in vivo, in vitro, and mouse models have allowed for better understanding of pathologic pathways to show the causal relationship between a change in a gene and the patient presentation. At the moment these models we have in some respects are still limited. As genetic technologies continue to advance it appears that we will be able to gain an even better perspective into the causes of gonadal dysgenesis, as well as better insight into human sexual development.
Testing is not typically indicated for gonadal dysgenesis unless a diagnosis of gonadal dysgenesis or a syndrome that has gonadal dysgenesis as a symptom is suspected. Most patients with gonadal dysgenesis will begin a necessary workup for their symptoms including an FSH and LH level and possibly pelvic imaging. Prenatal diagnosis may be pursued in cases of abnormal maternal triple or quadruple screens, or if the fetus presents with atypical features in the womb. For example, Turner syndrome may present prenatally as coaction of the aorta, intrauterine growth restriction, oligohydramnios, polyhydramnios, increased nuchal translucency, cystic hygroma, or nonimmune hydrops. Although these may be signs of Turner syndrome, a definitive diagnosis is only by a karyotype. A karyotype involves sending whole blood in a sodium heparin tube to the lab for testing, which may take up to a week, but a rushed result utilizing fluorescence in situ hybridization can identify monosomy X in under 24 hours.
Early recognition can help prevent growth failure and hearing problems as well as better manage chronic renal and cardiac conditions associated with Turner syndrome. A karyotype in an older child is necessary when there is high suspicion of Turner syndrome. For example, if a child has growth delay or lack of signs of puberty and secondary sexual characteristics, or if a child exhibited other signs such as a webbed neck or widely spaced nipples, it would serve as an indication for a karyotype. If high suspicion exists of a Turner syndrome diagnosis and initial blood karyotype is normal, another tissue should be tested such as skin to determine the child’s genetic make-up. All patients should also have analysis to determine if there is any presence of a Y chromosome, due to the risk of gonadoblastoma and germ cell tumor. Analysis of a Y chromosome should be performed in the prenatal period as well. Similar to Turner syndrome testing is also indicated for 46 XY complete gonadal dysgenesis when clinical findings suspect the diagnosis. A patient with delayed puberty or amenorrhea that has elevated basal LH and FSH levels and other causes for amenorrhea and delayed puberty ruled out can have a karyotype performed. Pelvic ultrasound or MRI may also reveal streak gonads which would indicate a karyotype. 46 XX gonadal dysgenesis will present similarly to 46 XY gonadal dysgenesis with delayed puberty, amenorrhea, increased LH and FSH levels, and streak gonads may be present; again clinical suspicion is the leading indication for testing in this disorder.
In all patients with suspected gonadal dysgenesis as discussed with Turner syndrome determination of whether a Y chromosome is present, including mosaic as well as partial and fragment Y chromosomal forms is necessary due to risks of gonadoblastoma and germ cell tumor associated with the retained gonads. After initial analysis and karyotype a specialist, most likely an endocrinologist, might perform further testing for specific gene mutations to try to determine the cause of the patient’s gonadal dysgenesis as well as gain an understanding of what other symptoms they may develop based specific genetic alterations. The specific genetic testing to be performed is determined by the clinical presentation of the patient and their symptomatic presentation. The genes with known associations to their symptoms can be tested. In addition to the above testing patients who have evidence of a Y chromosome as well as evidence of a mass on the gonad will need to have a biopsy performed as well as tumor markers including AFP, LDH, and beta-hCG to determine the presence of gonadoblastoma or germ cell tumor. Although genetic testing is an essential part of the diagnosis and management of gonadal dysgenesis the patients will undergo a multitude of testing during their lifetime to aid in the management of their condition. This testing can include basic labs CBC/CMP, echocardiography, renal ultrasound and much more to ensure all the patient's associated symptoms are addressed and managed.
Gonadal dysgenesis develops due to genetic alterations leading to impaired gonadal development. When the gonads do not develop properly, it leads to issues in the development of both internal and external genitalia. All patients with gonadal dysgenesis will have at least some dysfunction within the hypothalamic pituitary gonadal axis. The hypothalamus secretes GnRH which acts on the pituitary to release LH and FSH. LH and FSH go on to act on the gonads which in turn produce sex hormones in the form of estrogen and testosterone. Due to a lack of gonadal development seen in gonadal dysgenesis, the gonads respond either minimally or not at all to LH and FSH stimulation, leading to decreased production of estrogen and testosterone as well as decreased production of ovarian follicles and sperm.
Complete 46 XY gonadal dysgenesis in which the lack of the SRY gene activating the body’s processes to enact male development results in the body relying on the default processes which allows the Mullerian structures to develop internally. Mullerian structures develop into the female anatomy including the fallopian tubes, uterus, and cervix. Due to the lack of testicular development in these males, there is a lack of testosterone production which inhibits the development of male external genitalia, so these males will tend to present with female external genitalia. Patients with incomplete or partial 46 XY gonadal dysgenesis, or patients with mosaic forms of the disease with a Y chromosome it appears that there is a mixture of development of both male and female internal genitalia. In the 46 XY with incomplete gonadal dysgenesis, it appears there is incomplete differentiation of the internal genitalia likely due to insufficient amounts of testosterone and Mullerian inhibiting hormone during the early stages of development. These patients range from having non-functional streak gonads to partially functioning gonads due to the incomplete development. Patient’s with mosaic forms of the disease as seen in Turner syndrome with cell lines containing a Y chromosome will also have a mixture of development resulting in partial or non-functioning gonads and internal genitalia. These patients will have ambiguous external genitalia due to the reduced influence of the Y chromosome.
Patients with complete 46 XX gonadal dysgenesis will tend to have female internal and external genitalia and will typically have streaked or hypoplastic ovaries. Turner syndrome patients have the same processes that affect their gonadal development resulting in atrophy of the ovarian follicles and the development of streak ovaries. As discussed above due to the gonads being unresponsive to FSH and LH female patients with gonadal dysgenesis will have amenorrhea, and most will be infertile. Some cases of spontaneous pregnancy in mosaic Turner syndrome patients have been documented, likely due to partial functioning of the ovary. Males with gonadal dysgenesis will also tend to be infertile due to underdeveloped or lack of testes. The symptoms other than gonadal dysgenesis seen in syndromes such as Turner syndrome are due to the mutations and alterations in some of the secondary genes described above, for example the short stature seen in Turner syndrome which is believed to be caused by decreased sensitivity to growth hormone, decreased availability of growth hormone, or decreased production of growth hormone.
Gonadal dysgenesis is clinically significant due to the issues it may cause to the physical and mental well-being of the patients affected by it. Patients with gonadal dysgenesis will likely need hormone therapy to develop appropriate secondary sexual characteristics. Even with hormone therapy a large percentage of these patients may not develop similarly to their peers and will remain infertile; this can have huge impacts on the patient’s mental health. Children and adults with gonadal dysgenesis may feel insecure about their physical appearance. For example, when an individual is genetically male but has female external genitalia as in 46, XY gonadal dysgenesis, it can be a point of concern and stress for both the patient and the patient’s parents. Females with gonadal dysgenesis may also be concerned when they do not develop menses or secondary sexual characteristics like their peers. Being able to produce offspring of our own is also a desire of many people in our society and being infertile and not being able to do that may cause a great deal of emotional turmoil. Proper fertility counseling, discussion of the patient’s options, and referral to the appropriate services are vital in caring for these patients with infertility. In patients with gonadal dysgenesis that contains Y chromosomal material, there is also an increased risk for the development of gonadoblastoma, dysgerminoma, teratoma, and choriocarcinoma, which requires removal of the gonads early on in life to prevent tumor formation.
Additionally, a large number of patients with gonadal dysgenesis will have other associated health problems. As seen in Turner syndrome there can be significant cardiac and renal abnormalities that will require assessment and management by a physician. Turner syndrome patients also commonly have short stature that will indicate treatment with growth hormone early on to decrease growth stunting. Many other possible conditions correlate with gonadal dysgenesis, and it is essential to keep an eye out for these complications and utilize multiple specialists to create a care team for each patient on an individual basis. Gonadal dysgenesis is a complex condition with associated symptoms spanning across many organ systems. Our understanding of gonadal dysgenesis is limited but improving with time. Clinicians must be familiar with gonadal dysgenesis so that when a patient appears with the clinical characteristics of the condition they do not go unnoticed and the patient can go on to receive the treatment they need to improve their development and decrease their mortality.
|||Chacko E,Graber E,Regelmann MO,Wallach E,Costin G,Rapaport R, Update on Turner and Noonan syndromes. Endocrinology and metabolism clinics of North America. 2012 Dec; [PubMed PMID: 23099266]|
|||Rocha VB,Guerra-Júnior G,Marques-de-Faria AP,de Mello MP,Maciel-Guerra AT, Complete gonadal dysgenesis in clinical practice: the 46,XY karyotype accounts for more than one third of cases. Fertility and sterility. 2011 Dec; [PubMed PMID: 21982289]|
|||FERGUSON-SMITH MA, KARYOTYPE-PHENOTYPE CORRELATIONS IN GONADAL DYSGENESIS AND THEIR BEARING ON THE PATHOGENESIS OF MALFORMATIONS. Journal of medical genetics. 1965 Jun; [PubMed PMID: 14295659]|
|||Morgan T, Turner syndrome: diagnosis and management. American family physician. 2007 Aug 1; [PubMed PMID: 17708142]|
|||Hochwagen A, Meiosis. Current biology : CB. 2008 Aug 5; [PubMed PMID: 18682199]|
|||Hall H,Hunt P,Hassold T, Meiosis and sex chromosome aneuploidy: how meiotic errors cause aneuploidy; how aneuploidy causes meiotic errors. Current opinion in genetics [PubMed PMID: 16647844]|
|||Nistal M,Paniagua R,González-Peramato P,Reyes-Múgica M, Perspectives in Pediatric Pathology, Chapter 5. Gonadal Dysgenesis. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2015 Jul-Aug; [PubMed PMID: 25105336]|
|||Meyers CM,Boughman JA,Rivas M,Wilroy RS,Simpson JL, Gonadal (ovarian) dysgenesis in 46,XX individuals: frequency of the autosomal recessive form. American journal of medical genetics. 1996 Jun 28; [PubMed PMID: 8826428]|
|||Bashamboo A,Eozenou C,Rojo S,McElreavey K, Anomalies in human sex determination provide unique insights into the complex genetic interactions of early gonad development. Clinical genetics. 2017 Feb; [PubMed PMID: 27893151]|
|||Mortensen KH,Andersen NH,Gravholt CH, Cardiovascular phenotype in Turner syndrome--integrating cardiology, genetics, and endocrinology. Endocrine reviews. 2012 Oct; [PubMed PMID: 22707402]|
|||Zinn AR,Ross JL, Turner syndrome and haploinsufficiency. Current opinion in genetics [PubMed PMID: 9690998]|
|||Zinn AR,Ross JL, Molecular analysis of genes on Xp controlling Turner syndrome and premature ovarian failure (POF). Seminars in reproductive medicine. 2001 Jun; [PubMed PMID: 11480911]|
|||Ledig S,Röpke A,Haeusler G,Hinney B,Wieacker P, BMP15 mutations in XX gonadal dysgenesis and premature ovarian failure. American journal of obstetrics and gynecology. 2008 Jan; [PubMed PMID: 17826728]|
|||Granados A,Alaniz VI,Mohnach L,Barseghyan H,Vilain E,Ostrer H,Quint EH,Chen M,Keegan CE, MAP3K1-related gonadal dysgenesis: Six new cases and review of the literature. American journal of medical genetics. Part C, Seminars in medical genetics. 2017 Jun; [PubMed PMID: 28504475]|
|||MacLaughlin DT,Donahoe PK, Sex determination and differentiation. The New England journal of medicine. 2004 Jan 22; [PubMed PMID: 14736929]|
|||McCann-Crosby B,Mansouri R,Dietrich JE,McCullough LB,Sutton VR,Austin EG,Schlomer B,Roth DR,Karaviti L,Gunn S,Hicks MJ,Macias CG, State of the art review in gonadal dysgenesis: challenges in diagnosis and management. International journal of pediatric endocrinology. 2014; [PubMed PMID: 24731683]|
|||Klein DA,Emerick JE,Sylvester JE,Vogt KS, Disorders of Puberty: An Approach to Diagnosis and Management. American family physician. 2017 Nov 1; [PubMed PMID: 29094880]|